Several classes of medication can lower cortisol, each working through a different mechanism: some block cortisol production in the adrenal glands, some target the pituitary gland to reduce the hormonal signal that drives cortisol output, and one blocks cortisol from acting on its receptor without reducing the hormone itself. The choice depends on why cortisol is too high in the first place, whether the situation is an emergency or a chronic management problem, and what side effects a patient can tolerate. Most of these drugs were developed for Cushing’s syndrome, but the landscape has shifted in recent years with new approvals and evolving combination strategies.
Drugs That Block Cortisol Production in the Adrenal Glands
The largest and most commonly used group of cortisol-lowering medications are steroidogenesis inhibitors. These drugs interfere with the enzymes the adrenal glands need to manufacture cortisol. They don’t fix whatever is driving the excess; they just reduce the factory’s output. The two longest-established options are ketoconazole and metyrapone, which have been workhorses in Cushing’s treatment for decades and remain among the most reliably effective agents, whether used alone or together.1Europe PMC. New options for the medical treatment of Cushing’s syndrome
Ketoconazole was originally developed as an antifungal drug, but clinicians noticed it suppressed cortisol as a side effect. It works by blocking key enzymes in the cortisol production pathway, and it also appears to prevent the expected compensatory rise in the pituitary hormone ACTH that would normally push cortisol back up.2PubMed. Use of ketoconazole in the treatment of Cushing’s syndrome The main concern with ketoconazole is liver toxicity: patients on it need regular blood tests to monitor liver function. It also interacts with a long list of other medications because it affects liver enzymes involved in drug metabolism.
Metyrapone takes a more targeted approach, inhibiting the final step of cortisol synthesis. A single dose can drop cortisol levels within two hours, and that effect holds at four hours.3PubMed. Short and long-term responses to metyrapone in the medical management of 91 patients with Cushing’s syndrome That fast action makes it useful when you need cortisol controlled quickly. The trade-off is that blocking that particular enzyme can cause a buildup of cortisol precursors, some of which have androgenic (masculinizing) effects, so women on metyrapone sometimes develop acne or excess hair growth.
The newest steroidogenesis inhibitor to reach the clinic is osilodrostat, approved by the European Medicines Agency in 2020. It also targets the final enzyme in cortisol synthesis but binds more potently and specifically than metyrapone.4PubMed Central. Osilodrostat in Cushing’s disease: the management of its efficacy and the pitfalls of post-surgical results Real-world data have been encouraging: in one study tracking patients with ACTH-dependent Cushing’s, a therapeutic effect was reached in about nine out of ten patients within two weeks, at relatively modest doses. Morning cortisol normalized in roughly nine out of ten cases, and urinary cortisol normalized in three out of four.5PubMed Central. Individualized osilodrostat treatment for patients with ACTH-dependent Cushing’s syndrome: real-world evidence Those numbers are impressive for a disease that has historically been difficult to control with medication alone.
Levoketoconazole is another recent arrival, essentially a purified form of the active component of ketoconazole. The idea is that isolating the specific mirror-image molecule responsible for cortisol suppression may improve efficacy and reduce some of ketoconazole’s liver-related risks.6PubMed Central. New Trends in Treating Cushing’s Disease
When Only an IV Drug Will Do
All of the medications above are taken by mouth. That creates a problem when someone is critically ill, unable to swallow, or in a cortisol crisis that needs to be tamed within hours rather than days. Etomidate, an anesthetic agent given intravenously, is the only IV option for treating dangerously high cortisol. It is used off-label, typically in intensive-care settings, at doses far lower than those needed for sedation. A systematic review found that higher initial infusion rates led to faster cortisol reduction, and that using etomidate as first-line therapy in ICU settings was associated with quicker results compared with using it after oral drugs had already failed. About four out of five patients survived to receive definitive treatment such as surgery.7PubMed Central. Etomidate in Severe Cushing Syndrome: A Systematic Review Etomidate is strictly a bridge, used to buy time until a longer-term solution can be put in place.
Targeting the Pituitary Gland Directly
When excess cortisol is driven by a small tumor on the pituitary gland (the most common form of Cushing’s disease), another strategy is to go after the source of the problem: the pituitary itself. Two classes of drugs do this by activating receptors on the tumor cells that dial down their hormone output.
Pasireotide is a somatostatin analog, meaning it mimics a natural hormone that tells various glands to quiet down. What makes pasireotide different from older somatostatin drugs is its strong affinity for a specific receptor subtype that is abundant on the pituitary tumors that drive Cushing’s disease, and that receptor doesn’t get switched off by high cortisol the way other subtypes do.8PubMed Central. Clinical use of pasireotide for Cushing’s disease in adults In a large phase 3 trial, pasireotide lowered cortisol levels and reduced clinical signs and symptoms of the disease.9PubMed. A 12-month phase 3 study of pasireotide in Cushing’s disease The catch is hyperglycemia: pasireotide often drives blood sugar up, sometimes severely, so patients frequently need diabetes medication alongside it. That has limited its use in people who already have trouble controlling their blood sugar.
Cabergoline comes from a completely different angle. It’s a dopamine agonist, better known as a treatment for prolactin-secreting pituitary tumors and Parkinson’s disease. Some corticotroph tumors (the pituitary cells that overproduce ACTH) have dopamine receptors, and activating those receptors can reduce ACTH secretion.10PubMed Central. Update in the medical therapy of Cushing’s disease The results are more modest than with pasireotide: in a large retrospective study, about 40% of patients on cabergoline alone normalized their urinary cortisol within a year.11PubMed. Cabergoline for Cushing’s disease: a large retrospective multicenter study Another earlier study found a similar 40% long-term success rate over two years, though initial response rates were higher at 75%, suggesting some patients “escape” the drug’s effect over time.12PubMed. The medical treatment of Cushing’s disease: effectiveness of chronic treatment with the dopamine agonist cabergoline in patients unsuccessfully treated by surgery Cabergoline is generally well tolerated compared with other Cushing’s drugs, which makes it a reasonable first-line attempt for milder cases, even knowing it won’t work for everyone.
Blocking Cortisol at the Receptor
Mifepristone takes an entirely different approach: instead of reducing cortisol production, it blocks cortisol from binding to its receptor. The hormone is still circulating (and in fact rises because the body’s feedback loop senses less cortisol activity and ramps up production), but it can’t exert its effects on tissues. This makes mifepristone useful when production-blocking drugs have failed or aren’t tolerated, and it has a rapid onset of action that makes it particularly valuable in acute crises, including cortisol-induced psychosis.13PubMed. Mifepristone (RU 486) in Cushing’s syndrome
The downside of receptor blockade is that monitoring becomes tricky. Because cortisol levels in the blood actually go up rather than down, you can’t use the usual blood and urine cortisol tests to gauge whether the drug is working. Clinicians have to rely on clinical signs: Is the patient’s blood sugar improving? Is their blood pressure coming down? Are the physical features of Cushing’s resolving? That kind of subjective assessment makes dose adjustments harder. Mifepristone is also a progesterone receptor blocker, which means it can’t be used in pregnancy and may cause endometrial thickening in women.
Relacorilant is a newer selective cortisol receptor blocker designed to avoid mifepristone’s progesterone-blocking effects.6PubMed Central. New Trends in Treating Cushing’s Disease By targeting only the glucocorticoid receptor, it sidesteps the reproductive side effects while still countering cortisol’s action on metabolism, blood sugar, and blood pressure. It represents an attempt to keep the benefits of receptor blockade while cleaning up the side-effect profile.
Mitotane for Adrenal Cancer and Severe Cases
Mitotane occupies its own category because it doesn’t just inhibit cortisol synthesis; it actively destroys adrenal tissue. Originally developed as a treatment for adrenocortical carcinoma, mitotane ruptures the membranes of mitochondria within adrenal cells in a dose-dependent fashion, shutting down steroid production from multiple angles.14PubMed Central. A Review on Mitotane: A Target Therapy in Adrenocortical Carcinoma It also reduces the expression of proteins that transport cholesterol into mitochondria, blocking the raw-material supply that the adrenal glands need to begin making any steroid hormone at all.
Because mitotane destroys the cells that make cortisol (and aldosterone, and sex steroids), patients on it almost always need glucocorticoid replacement therapy. They are, in effect, trading pathological overproduction for controlled deficiency that gets managed with hydrocortisone pills. It is a powerful tool in adrenal cancer, where the goal is to kill tumor tissue and suppress the hormones that a functioning tumor churns out.15PubMed Central. A review of mitotane in the management of adrenocortical cancer Mitotane is rarely the first choice for benign causes of high cortisol because of its toxicity and the permanent adrenal damage it can cause.
Combining Drugs for Better Control
No single medication normalizes cortisol in every patient, and some people escape control after initially responding. That reality has pushed clinicians toward combining drugs from different classes, the logic being that hitting multiple targets at once (reduced ACTH from the pituitary plus reduced cortisol production in the adrenal glands, for example) should produce additive or even synergistic effects. Studies of combination therapy suggest this works: pairing drugs yields a higher probability of long-term cortisol control at lower individual doses, which tends to mean fewer side effects and a lower rate of treatment escapes.16PubMed. Medical combination therapies in Cushing’s disease The combinations that have the most evidence behind them involve ketoconazole paired with cabergoline or pasireotide, though clinicians mix and match depending on the patient’s specific tumor type and tolerance profile.
Combination approaches are especially common after pituitary surgery that didn’t fully cure the disease. A patient who has had most of a pituitary tumor removed but still has residual cortisol excess might get a lower dose of ketoconazole to mop up what the adrenals are still producing, plus cabergoline to keep ACTH in check from whatever tumor cells remain. The art is in balancing efficacy against the cumulative side effects of multiple drugs.
The Risk of Overshooting
All cortisol-lowering medications carry a shared and sometimes dangerous risk: they can work too well. Driving cortisol below normal is called adrenal insufficiency, and it produces fatigue, nausea, dizziness, low blood pressure, and in severe cases can be life-threatening. The symptoms of adrenal insufficiency overlap with the symptoms of glucocorticoid withdrawal, which makes it genuinely hard to tell what is happening when a patient on these drugs starts feeling terrible.17PubMed Central. Update and Practical Recommendations for the Use of Medical Treatment of Cushing Syndrome
Two dosing strategies have emerged to manage this risk. The first, called titration, involves starting low and slowly increasing the dose while monitoring cortisol. The second, called block-and-replace, involves giving a high enough dose to suppress cortisol production completely and then replacing the missing hormone with a fixed dose of hydrocortisone. Block-and-replace removes the guesswork of finding the perfect suppression dose, but it means the patient is taking two drugs instead of one. With osilodrostat specifically, rates of low cortisol during the early titration phase were substantial, running as high as half of patients in one clinical trial. French experts now recommend that all patients starting osilodrostat be given an emergency hydrocortisone kit and written instructions for recognizing adrenal insufficiency, along with frequent morning cortisol checks in the first weeks of treatment.18PubMed Central. Use of osilodrostat in a block-and-replace and titration strategy for cushing’s syndrome: a position paper by French experts
When High Cortisol Comes from Prescription Steroids
Not all high cortisol comes from tumors or overactive glands. The most common cause of elevated cortisol in the real world is taking prescribed glucocorticoid drugs like prednisone, prednisolone, or dexamethasone for conditions such as asthma, autoimmune disease, or organ transplant management. In these cases, the excess cortisol is iatrogenic, meaning the treatment itself is the cause, and the solution isn’t to add another drug on top. It’s to taper the steroid carefully.
Tapering matters because prolonged steroid use suppresses the body’s own cortisol production. The adrenal glands essentially go to sleep when external steroids are providing more than enough. If you stop abruptly, the glands can’t wake up fast enough and you end up in adrenal crisis. The standard approach is to reduce the dose gradually: moderate-to-high doses can be tapered relatively quickly down to near-physiological levels while watching for signs of the underlying disease flaring up. Once close to the body’s natural cortisol output, the taper slows down to give the adrenal glands time to recover. Short- or intermediate-acting preparations like hydrocortisone or prednisolone, given in the morning to mimic the body’s natural cortisol rhythm, are preferred during this phase.19PubMed Central. The Glucocorticoid Taper: A Primer for the Clinicians
Recent data suggest this approach works well in practice. In one study tracking patients through a structured taper, each 1 mg dose reduction was associated with a meaningful rise in the body’s own morning cortisol, and larger reductions produced bigger cortisol recoveries. Among patients who completed the weaning process, about four in five succeeded, with no adrenal crises recorded.20PubMed Central. Glucocorticoid-induced adrenal insufficiency: physiological dose tapering promotes recovery The process requires patience, though. Some patients take months to fully regain normal adrenal function, and a minority may need low-dose replacement for longer.
Trilostane in Veterinary Medicine
If you found this article because your dog was diagnosed with Cushing’s, the medication landscape looks quite different. Trilostane, a competitive inhibitor of the enzyme needed for cortisol synthesis, is the drug of choice for pituitary-dependent hyperadrenocorticism in dogs.21PubMed Central. Update on the use of trilostane in dogs It was briefly used in humans in the UK but never gained widespread adoption for people, partly because other options proved more practical.
In dogs, trilostane is given once or twice daily, and there has been some debate about which approach works better. A study comparing the two found that twice-daily dosing produced more complete clinical recoveries, though the total daily dose and side-effect rates were similar between the two groups.22PubMed. Evaluation of 2 trilostane protocols for the treatment of canine pituitary-dependent hyperadrenocorticism: twice daily versus once daily Dogs on trilostane need regular ACTH stimulation tests to make sure the dose isn’t overshooting and causing adrenal insufficiency, the same core risk that plagues human cortisol-lowering therapy. Veterinarians typically recheck blood work a few weeks after any dose adjustment and then every few months once stable.
Cushing’s is far more common in dogs than in people, which means trilostane has an enormous real-world evidence base in veterinary practice. That experience has actually fed back into human endocrinology: veterinary observations about the drug’s speed of action, its tendency to cause adrenal necrosis at high doses, and the importance of twice-daily dosing to maintain around-the-clock control have all informed how researchers think about cortisol suppression strategies more broadly.